论文部分内容阅读
目的观察多西紫杉醇联合卡培他宾方法治疗晚期胃癌的近期疗效和毒副反应。方法19例晚期胃癌患者,给予多西紫杉醇30mg/m2第1、8、15天静滴卡培他宾1000mg/m2,2次/d,第1～4天,口服,28天为1周期,2个周期后以WHO评价标准评价疗效和毒性,结果全组19例均可评价,其中完全缓解(CR)0例,部分缓解(PR)9例,稳定(SD)7例,进展(PD)3例,总有效率(CR+PR)47.3%。中位肿瘤进展时间(TTP)5.1个月,中位生存时间(MST)10.6个月。毒副反应主要是骨髓抑制,发生率63.1%,其次为手足综合征31.5%,消化道反应、恶心呕吐发生率为21%,口腔黏膜炎为15.7%,腹泻26.3%,周围神经毒性发生率为10.5%。结论多西紫杉醇联合卡培他宾治疗晚期胃癌近期疗效较好,毒副反应小,值得进一步研究应用。
Objective To observe the short-term curative effect and toxicity of docetaxel combined with capecitabine in the treatment of advanced gastric cancer. Methods Nineteen patients with advanced gastric cancer were treated with docetaxel 30 mg / m2 on day 1,8,15 for intravenous infusion of capecitabine 1000 mg / m2 twice daily for 1 day to 4 days orally for 28 days for one cycle. After 2 cycles, the curative effect and toxicity of the two groups were evaluated by WHO evaluation criteria. Results All the patients were evaluated in 19 cases, including 0 cases of complete remission (CR), 9 cases of partial remission (PR), 7 cases of stable (SD) 3 cases, the total effective rate (CR + PR) 47.3%. Median tumor progression time (TTP) 5.1 months, median survival time (MST) 10.6 months. Toxicity was mainly myelosuppression, the incidence of 63.1%, followed by hand-foot syndrome 31.5%, digestive tract reactions, nausea and vomiting was 21%, oral mucositis was 15.7%, diarrhea 26.3%, the incidence of peripheral neurotoxicity was 10.5%. Conclusion Docetaxel combined with capecitabine in the treatment of advanced gastric cancer has better curative effect and less toxic side effects, which deserves further study.